invasive meningococcal disease (imd) is a severe bacterial infectious disease with high mortality and morbidity rates worldwide. in recent years, industrialised countries have implemented vaccines targeting imd in their national immunisation programmes (nips). in 2002, the netherlands successfully implemented a single dose of meningococcal serogroup c conjugate vaccine at the age of 14 months a...

Due to the COVID-19 pandemic, many countries have implemented vaccination program combat spread of virus in order return a normal life after quarantine period. The success has shown decrease infection and death besides practice physical distancing. This paperwork will discuss category people who doubt, confidence their view towards National Immunisation Programme (NIP) Malaysia. A quantitative ...

Invasive meningococcal disease (IMD) is a severe bacterial infectious disease with high mortality and morbidity rates worldwide. In recent years, industrialised countries have implemented vaccines targeting IMD in their National Immunisation Programmes (NIPs). In 2002, the Netherlands successfully implemented a single dose of meningococcal serogroup C conjugate vaccine at the age of 14 months a...

This report summarises national passive surveillance data reported to the Therapeutic Goods Administration (TGA) to 31 August 2009 for adverse events following immunisation (AEFI) in children aged less than 7 years who received vaccines between 1 January and 30 June 2009. The report includes all vaccines administered to children in this age group with a focus on the vaccines included in the fun...

This report summarises national passive surveillance data reported to the Therapeutic Goods Administration (TGA) to 31 August 2012 for adverse events following immunisation (AEFI) for children aged <7 years who received vaccines between 1 January and 30 June 2012. The report includes all vaccines administered to children in this age group with a focus on the vaccines included in the funded Nati...

1 Gluck T. Vaccinate your immunocompromised patients! Rheumatology 2006;45:9–10. 2 BSR National guidelines for the monitoring of second line drugs. London: British Society for Rheumatology, 2000. 3 Summary of Flu immunisation policy – Department of health. http://www.dh.gov.uk/ PolicyAndGuidance/HealthAndSocialCareTopics/Flu. 4 Bridges MJ, Coady D, Kelly CA et al. Factors influencing uptake of ...

BACKGROUND AND AIMS To evaluate the National Immunisation Programme (NIP) a population-based cross-sectional seroepidemiological study was performed in the Netherlands. We assessed diphtheria antitoxin levels in the general Dutch population and in low vaccination coverage (LVC) areas where a relatively high proportion of orthodox Protestants live who decline vaccination based on religious groun...

Corresponding author: Dr Glenda Lawrence, National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Locked Bag 4001, Westmead NSW 2145. Telephone:+61 2 9845 1433. Facsimile: +61 2 9845 1418. Email: [email protected] This report summarises national passive surveillance data contained in the Adverse Drug Reactions Advisory Committee (ADRAC) database at 30 Septem...

In 2006/2007 a large serum bank was established by means of a cross-sectional population-based study. This serum bank will be used to evaluate the Dutch national immunisation programme (NIP) by serosurveillance and additional immunological and epidemiological research. In this paper we describe the design of this population-based cross-sectional serosurvey and report the participation rates as ...

Objectives This study was designed to report incidence and characteristics of selected adverse events following immunisation which have consistent causal association (AEFIc) with Measles-Mumps-Rubella (MMR) vaccination given at the age of one year in the National Immunisation Programme of Sri Lanka. Methods The data presented here were obtained from a cohort event monitoring study. It was car...